PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor.
PN6047 is Phase II ready!
Company Details
- Employees
- 10
- Founded
- -
- Address
- Medicon Village, Sheeletorget 1,sweden
- Phone
- +46 (0)705 44 32 50
- pe****@****ovo.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- pharmnovo.com
- Keywords
- CNS, Neurology, Chronic Pain Treatment, BioPharma, Bioscience, Chemistry, Biotechnology, Pharmacology, Proteins, DOR agonists, Delta opioid receptor.
- HQ
- Lund
Pharmnovo Questions
Pharmnovo's helpline number is +46 (0)705 44 32 50
Pharmnovo's website is pharmnovo.com
Pharmnovo's LinkedIn profile is https://se.linkedin.com/company/pharmnovo
Pharmnovo has
10 employees.
View email and phone details for 10
employees at Pharmnovo.
Pharmnovo's industry is
Biotechnology Research
Pharmnovo's top competitors are
Karolinska Development,
Sciety,
Pharmnova,
Atai Life Sciences,
Stalicla,
Mendus Ab,
Coegin Pharma Ab,
Capitainer,
Clearmind Medicine,
Neogap Therapeutics Ab.
Pharmnovo's support email address is per.von.mentzer@pharmnovo.com
Pharmnovo's categories are Biotechnology Research
Pharmnovo's founding year is 2008
